KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Equity (2021 - 2023)

Historic Return on Equity for AbCellera Biologics (ABCL) over the last 4 years, with Q3 2024 value amounting to 0.04%.

  • AbCellera Biologics' Return on Equity rose 700.0% to 0.04% in Q3 2024 from the same period last year, while for Sep 2024 it was 0.04%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 0.15% for FY2024, which is 200.0% down from last year.
  • According to the latest figures from Q3 2024, AbCellera Biologics' Return on Equity is 0.04%, which was up 700.0% from 0.07% recorded in Q2 2024.
  • AbCellera Biologics' 5-year Return on Equity high stood at 0.32% for Q1 2021, and its period low was 0.13% during Q4 2023.
  • For the 4-year period, AbCellera Biologics' Return on Equity averaged around 0.08%, with its median value being 0.13% (2022).
  • Its Return on Equity has fluctuated over the past 5 years, first plummeted by -3100bps in 2023, then surged by 700bps in 2024.
  • AbCellera Biologics' Return on Equity (Quarter) stood at 0.16% in 2021, then fell by -18bps to 0.13% in 2022, then plummeted by -198bps to 0.13% in 2023, then soared by 66bps to 0.04% in 2024.
  • Its last three reported values are 0.04% in Q3 2024, 0.07% for Q2 2024, and 0.09% during Q1 2024.